as 11-12-2024 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 1.1B | IPO Year: | 2020 |
Target Price: | $20.88 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.61 | EPS Growth: | N/A |
52 Week Low/High: | $5.60 - $12.14 | Next Earning Date: | 11-06-2024 |
Revenue: | $10,006,000 | Revenue Growth: | -61.22% |
Revenue Growth (this year): | -59.48% | Revenue Growth (next year): | -93.56% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Bergstrom Donald A | RLAY | President, R&D | Oct 28 '24 | Sell | $6.06 | 2,688 | $16,289.28 | 520,745 | |
Adams Brian | RLAY | Chief Legal Officer | Oct 28 '24 | Sell | $6.06 | 1,632 | $9,889.92 | 321,907 | |
Catinazzo Thomas | RLAY | Chief Financial Officer | Oct 28 '24 | Sell | $6.02 | 9,102 | $54,905.12 | 311,496 | |
Bergstrom Donald A | RLAY | President, R&D | Sep 27 '24 | Sell | $7.51 | 648 | $4,866.48 | 520,745 | |
Adams Brian | RLAY | Chief Legal Officer | Sep 27 '24 | Sell | $7.51 | 295 | $2,215.45 | 321,907 | |
Catinazzo Thomas | RLAY | Chief Financial Officer | Sep 27 '24 | Sell | $7.48 | 6,457 | $48,183.97 | 311,496 | |
Rahmer Peter | RLAY | See remarks | Sep 27 '24 | Sell | $7.51 | 245 | $1,839.95 | 391,684 |
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
GlobeNewswire
6 days ago
GlobeNewswire
13 days ago
Simply Wall St.
16 days ago
Zacks
2 months ago
Motley Fool
2 months ago
MT Newswires
2 months ago
MT Newswires
2 months ago
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.